UPDATE: Piper Jaffray On Nektar Also Notes 'We look forward to the melanoma/PIVOT-02 cohort update at SITC this weekend and are encouraged to see more of the pipeline advance into clinical development (255/IL-15 and 358/T-reg)'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/07/2019 18:34